The Peter and Devon Briger Foundation II is primarily a biomedical research funder with a strong, targeted interest in leiomyosarcoma and cancer immunotherapy, backing translational efforts to develop next-generation cell and immune therapies. Most dollars flow to major research centers and universities to support disease-specific projects and translational science, while a small number of modest gifts fund unrelated interests (e.g., athletics in Israel, general higher-education support, and local community services). The foundation’s giving reflects strategic, impact-oriented investments rather than broad-based philanthropy.
The most distinctive feature of The Peter and Devon Briger Foundation II is its concentration in leiomyosarcoma and cancer immunotherapy, including a $5,000,000 grant to the University of California San Francisco Foundation for engineering a next-generation cell therapy for leiomyosarcoma. That single grant signals a clear preference for translational research, where funded work is aimed at moving from lab science toward treatment development. The foundation also backed the La Jolla Institute for Immunology with $1,687,786 for leiomyosarcoma research, reinforcing the same disease-focused thread across different research institutions. Its recent awards show a mix of large, mission-specific research grants and smaller support grants for other causes. A $500,000 grant to the Parker Institute for Cancer Immunotherapy supported an immunotherapy research initiative, while more modest awards also went to Israel Water Polo Association and Collier Services Foundation Inc. The pattern suggests a funder that directs most of its resources to biomedical science, especially projects tied to rare cancer therapy development, while also making occasional smaller grants outside that core area. The foundation’s giving is structured around named projects and institutional research support rather than broad, open-ended philanthropy.
In leiomyosarcoma research, the foundation supported multiple institutions with distinct project goals. The University of California San Francisco Foundation received $5,000,000 for engineering a next-gen cell therapy for leiomyosarcoma, and the La Jolla Institute for Immunology received $1,687,786 for leiomyosarcoma research. Cancer immunotherapy is another clear theme. The Parker Institute for Cancer Immunotherapy was awarded $500,000 for an immunotherapy research initiative, showing interest in work that can strengthen immune-based treatment pathways. The foundation also made a targeted grant tied to uterine leiomyosarcoma: The Milken Institute received $16,961 for accelerating therapy development for uterine leiomyosarcoma. Outside biomedical research, smaller grants also went to Israel Water Polo Association for general support and Collier Services Foundation Inc for general support.
$7.9M
$6M
$9.9M
$11.3M
Most grants fall between $2K and $126K, with a median of $2K.
25th Percentile
$2K
Median
$2K
75th Percentile
$126K
Top 2 recipient countries by grant volume for Peter and Devon Briger Foundation Ii.
| Rank | Country | Grants | Total | Share |
|---|---|---|---|---|
| 1 | United StatesDomestic | 9 | $7.7M | 81.8% |
| 2 | Israel |
Sign up for a free Kindora account to access AI-generated insights into this funder's giving patterns, decision-makers, and fit signals.
Get Started FreeFree Kindora accounts unlock side-by-side comparisons with foundations that share this funder's focus areas and giving profile.
Get Started FreeSign up free to see how well your nonprofit fits this funder, get an AI-generated pitch, and unlock similar foundations.
Highly concentrated giving characterized by a few very large grants to leading biomedical research institutions (one $5M award dominates), focused on disease-specific, translational projects; occasional smaller repeat or one-off grants to universities and niche non-research causes.
Notable grantees: University of California San Francisco Foundation, La Jolla Institute for Immunology, Parker Institute for Cancer Immunotherapy, Brown University, Collier Services Foundation Inc
Typical grants are small in the middle but with a wide upper tail: p25 is $1,750, median is $2,000, and p75 rises to $126,000. That distribution reflects a foundation that makes a few very large research awards alongside many much smaller gifts. The recent list also shows repeat giving to Collier Services Foundation Inc. in 2023, 2024, and 2025, suggesting some recipients are supported across multiple years rather than once only. The foundation is a private grantmaker with regional scope and does not fund individuals or make program-related investments. The visible pattern is project-specific support, often to institutions and named research initiatives.
Giving is concentrated in the United States, with the recipient country distribution showing 9 grants to US organizations and 2 to Israel. California appears often in the recent grants, including San Francisco, La Jolla, and Santa Monica. New Jersey also stands out because Collier Services Foundation Inc. in Wickatunk received multiple small grants across three years. Outside the US, the named international recipient is the Israel Water Polo Association. The foundation gives regionally, but its recipient locations show a strong California cluster with a smaller set of grants elsewhere.
Its recent grants center on leiomyosarcoma research and cancer immunotherapy. Examples include a $5,000,000 grant for a next-gen cell therapy for leiomyosarcoma, $1,687,786 for leiomyosarcoma research, and $500,000 for an immunotherapy research initiative.
Yes. Collier Services Foundation Inc. received grants in 2023, 2024, and 2025, with awards of $1,500, $2,000, and $2,000. That pattern shows some continued support across multiple years.
The median recent grant is $2,000, with a p25 of $1,750 and a p75 of $126,000. That means the foundation’s distribution includes many small awards, plus a smaller number of very large research grants.
The top state by grant count is New Jersey, while California appears frequently in the recent recipient list as well, including San Francisco, La Jolla, and Santa Monica. The recipient country distribution is 81.8% US and 18.2% Israel.
2025
Source: IRS Form 990-PF, fiscal year 2025.
| 2 |
| $70K |
18.2% |
Recipient country reflects the grantee's headquarters per IRS 990-PF and Schedule F filings, not the program's implementation country.
Most recent grants reported to the IRS.
| Recipient | Location | Amount | Year | Purpose |
|---|---|---|---|---|
| UNIVERSITY OF CALIFORNIA SAN FRANCISCO FOUNDATION | SAN FRANCISCO, CA | $5,000,000 | 2025 | ENGINEERING A NEXT-GEN CELL THERAPY FOR LEIOMYOSARCOMA |
| LA JOLLA INSTITUTE FOR IMMUNOLOGY | LA JOLLA, CA | $1,687,786 | 2025 | LEIOMYOSARCOMA RESEARCH |
| PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY | SAN FRANCISCO, CA | $500,000 | 2025 | IMMUNOTHERAPY RESEARCH INITIATIVE |
| ISRAEL WATER POLO ASSOCIATION | NE | $35,000 | 2025 | GENERAL SUPPORT |
| THE MILKEN INSTITUTE | SANTA MONICA, CA | $16,961 | 2025 | ACCELERATING THERAPY DEVELOPMENT FOR UTERINE LEIOMYOSARCOMA |
| COLLIER SERVICES FOUNDATION INC | WICKATUNK, NJ | $2,000 | 2025 | GENERAL SUPPORT |
| COLLIER SERVICES FOUNDATION INC | WICKATUNK, NJ | $2,000 | 2024 | GENERAL SUPPORT |
| BROWN UNIVERSITY | PROVIDENCE, RI | $250,000 | 2023 | BROWN ANNUAL FUND; ECONOMICS DEPARTMENT FUND |
| COLLIER SERVICES FOUNDATION INC | WICKATUNK, NJ | $1,500 | 2023 | GENERAL SUPPORT |
ENGINEERING A NEXT-GEN CELL THERAPY FOR LEIOMYOSARCOMA
IMMUNOTHERAPY RESEARCH INITIATIVE
ISRAEL WATER POLO ASSOCIATION
$35,000GENERAL SUPPORT
ACCELERATING THERAPY DEVELOPMENT FOR UTERINE LEIOMYOSARCOMA
COLLIER SERVICES FOUNDATION INC
$2,000GENERAL SUPPORT
COLLIER SERVICES FOUNDATION INC
$2,000GENERAL SUPPORT
BROWN UNIVERSITY
$250,000BROWN ANNUAL FUND; ECONOMICS DEPARTMENT FUND
COLLIER SERVICES FOUNDATION INC
$1,500GENERAL SUPPORT